Table 4 Comparison of major adverse events between the three treatment options
|  | Group-V1 (n = 43) | Group-V2 (n = 41) | Group-V3 (n = 43) | P Value | H |
|---|---|---|---|---|---|
Overall | 1 (2.3%) | 8 (19.5%) | 6 (14.0%) | < 0.05 | 6.189 |
Skin eruption | 0 | 1 (2.4%) | 0 | 0.350 | 2.098 |
Nausea | 1 (2.3%) | 6 (14.6%) | 1 (2.3%) | < 0.05 | 7.070 |
Dizziness | 1 (2.3%) | 2 (4.9%) | 1 (2.3%) | 0.745 | 0.588 |
Inappetence | 0 | 1 (2.4%) | 0 | 0.350 | 2.098 |
Abdominal pain | 0 | 0 | 3 (7.0%) | 0.051 | 5.955 |
Abdominal bloating | 0 | 0 | 1 (2.3%) | 0.377 | 1.953 |
Constipation | 0 | 0 | 1 (2.3%) | 0.377 | 1.953 |
Easy fatigability | 0 | 1 (2.4%) | 0 | 0.350 | 2.098 |